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Introduction
Subjects with airway obstruction are strongly
recommended to monitor their lung function,
which is particularly variable in asthma [1-5]. Peak
expiratory flow rate (PEFR) monitoring has been
strongly recommended by asthma guidelines [1],
and clinical studies [2] have shown that the routine
use of peak flow meters, along with a self-man-
agement plan and education programme, can lead
to a better control of asthma. Unlike PEFR, other
spirometrical measurements (in particular FEV1)
are difficult to perform regularly by asthma pa-
tients outside the lung clinic, the specialist outpa-
tient department, or the GP’s office, still being in-
frequent the use of appropriate and handy devices
for simple lung function measurements to be per-
formed at home, during work, or while travelling.
PIKO-1 is a recent electronic device for both
PEFR and FEV1 personal check: some of the most
relevant characteristics claimed are pocket size
(35 g weight; volume 7 cm x 5cm x 1.5 cm), with
the possibility of setting predicted values (accord-
ing to the ATS 1994 predicted values), the quality
control of respiratory manoeuvres, the storage of
several tests, and the precision of measurements.
PIKO-1 has been suggested as an adequate
tool for both screening and monitoring [6]; never-
theless, the precision of measurements should be
the crucial point that is faced when using simple
technologies for critical measures that can highly
affect the patient’s management [1, 7-8]. Since at
the time of the study start-up no data as been avail-
able to our knowledge on this particular topic, the
aim of the present study was to compare PEFR and
FEV1 values obtained from the PIKO-1 device and
from a conventional office spirometer in subjects
with airway obstruction.
Methods
Main technical characteristics and potential of
PIKO-1
As mentioned above, PIKO-1 (Pulmonary Da-
ta Services, Inc. - Ferraris Medical Ltd, Hertford,
UK) is able to measure the patient’s peak expirato-
ry flow rate (PEFR) together with the patient’s
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Background and Aim. Subjects with airway obstruc-
tion are strongly recommended to monitor their lung
function, which is particularly variable in asthma. Unlike
PEFR, other personal measurements (such as FEV1) are
still difficult to perform. PIKO-1 is the first electronic de-
vice for both PEFR and FEV1 personal check, but its pre-
cision has not yet been assessed. The aim of this study was
to compare PEFR and FEV1 values from PIKO-1 and
from a conventional spirometer in subjects with airway
obstruction.
Methods. In total, 352 subjects (217 men; 47.6 ± 19.0
years; 72.6 ± 15.0 kg; 168.1 ± 11.9 cm) performed sequen-
tial measurements using a PIKO-1 device and a spirome-
ter. Wilcoxon signed-rank test and sign test were used as
statistical tests.
Results. Mean FEV1 values from the spirometer and
PIKO-1, respectively, were 2.9 L ± 1.1 and 3.0 L ± 1.1, and
mean PEFR values were 466.1 L/min ± 164.5 SD and 426.3
L/min ± 151.6 SD. PIKO-1 proved to overestimate FEV1
values by 4% (p<0.0001) and to underestimate PEFR val-
ues by 8% (p<0.000) systematically.
Conclusions. The precision of both PIKO-1 measure-
ments (such as FEV1 and PEFR) have been assessed. 
PEFR and FEV1 measures should be reset by two differ-
ent constants. Nevertheless, PIKO-1 is a suitable and reli-
able device for the personal monitoring of obstructive pa-
tients in real life.
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forced expiratory volume in one second (FEV1).
Additionally, PIKO-1 has a built-in memory which
stores the values of the last 96 measurements per-
formed, as well as both the corresponding date and
time of their execution. It also stores and reports a
comparison of each measurement to the patient’s
reference value for that parameter. The patient may
review each of these measurements at any time,
thus eliminating the need for clumsy hand-written
and error-prone diaries. By using an integrated in-
frared port, this data can be downloaded from
PIKO-1 to a personal computer, where a Win-
dows-based tool allows physicians to monitor pa-
tients’ lung function.
Subjects
Following their informed consent, 352 consec-
utive unselected subjects (217 males; mean age =
47.6 years ± 19.0 SD; mean weight = 72.6 kg ±
15.0 SD; mean height = 168.1 cm ± 11.9 SD) per-
formed sequential measurements on a PIKO-1 de-
vice and on an office spirometer (Masterscreen,
Jaeger, Germany) at the same time of the day (9-11
am). All patients used the same PIKO-1, and the
mouthpiece was changed for each subject.
There were 259 asthma patients, with the re-
maining 93 subjects being affected with chronic
obstructive pulmonary disease (COPD). Patients
were characterised by different degrees of airway
obstruction in baseline; 67 were current smokers;
112 were ex-smokers and the remaining 173 had
never smoked. 244 patients regularly assumed res-
piratory drugs. Even though according to different
treatment strategies of treatment, bronchodilators
(mainly short- and long-acting β2 adrenergics)
used by the great majority of patients (n = 209),
while anti-inflammatory drugs (mainly inhaled
corticosteroids) were used by 136 subjects. The
number of subjects assuming combined medica-
tion was 189, while 68 patients were without any
active treatment. In order to avoid further causes of
variability, all patients on treatment stopped their
respiratory drugs 24 hours before both the PIKO-1
and the spirometrical tests. All patients performed
both respiratory manoeuvres: 50% of patients first
performed the PIKO-1 manoeuvre, while the other
50% first performed the spirometrical measure.
The patients’ compliance to both of the respiratory
manoeuvres was assessed by an expert dedicated
nurse.
The Masterscreen spirometer was calibrated
daily before measurements in accordance with the
internal calibration protocol, periodically checked
and validated by the ISO 9001-2000 procedures
for our lung department [9].
Statistics
The Wilcoxon signed-rank test and sign test
were used.
The agreement between FEV1 and PEF mea-
surements obtained by the PIKO-1 and by the Mas-
terscreen was assessed using the method proposed
by Bland and Altman [10] and according to the rec-
ommendations of Westgard [11]. Analyses were un-
dertaken using Stata 8.0 [12] and Matlab R13 [13].
Results
Spirometrical and PIKO-1 respiratory ma-
noeuvres were correctly performed and easily ob-
tained for all patients.
Mean FEV1 values from the Masterscreen
spirometer and the PIKO-1, respectively, were 2.9
L ± 1.1 SD and 3.0 L ± 1.1 SD, while mean PEFR
values were 466.1 L/min ± 164.5 SD and 426.3
L/min ± 151.6 SD from the Masterscreen spirom-
eter and the PIKO-1, respectively.
Comparison between FEV1-sp and FEV1pk
The correlation between measurements was
0.983 (95% CI = 0.979 – 0.986).
Error-in-variable regression
Varying the hypothesised reliability between
0.97 (3% of noise variance on the total variance)
and 1 (no measurement noise), the regression co-
efficient varied as shown in table 1: Bias calculat-
ed at the medical decision level FEV1 = 3L -0.109(95% CI: -0.131 – -0.087).
Present data was shown to suggest that PIKO-
1 was overestimating FEV1 measurements system-
atically by 4%. The standard deviation of the dif-
ference between measurements was 0.205.
More descriptive statistics for the differences
are as follows: Skewness of the differences = .26;
Kurtosis = 4.97.
Figure 1 shows the following data:
a) Probability distribution of the differences;
b) The quartile plot of the differences;
c) Comparison plot: FEV1measurements by PIKO
vs spirometric measurements; and
Table 1. - FEV1 measurements. Variability of regression coefficient by varying the hypothesised reliability between
0.97 (3% of noise variance on the total variance) and 1 (no measurement noise)
Reliability Intercept 95% CI Slope 95% CI
0.97 -0.102 -0.124 – -0.081 0.998 0.991 – 1.004
0.98 -0.071 -0.112 – -0.031 0.988 0.975 – 1.000
0.99 -0.041 -0.094 – 0.011 0.978 0.961 – 0.994
1.00 -0.012 -0.073 – 0.050 0.968 0.948 – 0.987
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d) Bland-Altman plot of the differences together
with the 95% limits of agreement.
Test for normality of the differences
The following tests were performed:
a) Skewness/Kurtosis tests for normality resulted
χ2 = 19.46, p-value < 0.001;
b) Shapiro-Wilk W test for normal data resulted z
= 4.64, p-value < 0.001.
These tests reject the normality hypothesis.
Fig. 1 (a and b) indicates that the distance of the
differences from the normal distribution is pro-
nounced on the tails of distribution.
Table 2. - Parameters of the regression models for FEV1 measures estimated by Deming regression for different
levels of variance ratio. The error variability appears unaffected by the changes in magnitude of measures
Intercept 95% CI Slope 95% CI
Difference -0.062 -0.124 – -0.000 -0.016 -0.035 – 0.004
Absolute difference 0.153 0.109 – 0.197 0.009 -0.005 – 0.023
Fig. 1. - a) probability distribution of the differences; b) the quantile plot of the differences;c) Comparison plot: FEV1 measurements by Piko vs.
spirometric measurements; d) Bland-Altman plot of the differences together with the 95% limits of agreements.
Relationship between difference and magnitude
See fig. 1 (d) and the following regressions.
We first assessed the difference between the two
methods based on the average of the two methods.
Moreover, we assessed the absolute difference be-
tween the two methods based on the average of the
two methods (tab. 2).
In terms of PEFR measurements, no relationship
was proved between the difference of the measure-
ments obtained from the two instruments and the ex-
tent of the same measurements. The trend of the error
variability (such as the standard deviation) remained
constant, even though the magnitude changed.
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Bias calculated at the medical decision level PEF
= 450
39.03 (95% CI: 33.26 – 44.80) We can con-
clude that PIKO-1 was systematically underesti-
mating PEFR measurements by 8%. The standard
deviation of the difference between measurements
was 54.84.
More descriptive statistics for differences are
as follows: Skewness of the differences = 0.98;
Kurtosis = 5.06
Figure 2 shows the following data:
a) Probability distribution
of the differences;
b) The quantile plot of the
differences;
c) Comparison plot: PEFR
measurements by PIKO
vs. spirometric measure-
ments; and
d) Bland-Altman plot of
the differences together
with the 95% limits of
agreement.
Table 3. - Error-in-variable regression of PEFR measurements. Variability of 
regression coefficient by varying the hypothesised reliability between 0.97 (3% of
noise variance on the total variance) and 1 (no measurement noise)
Reliability Intercept 95% CI Slope 95% CI
0.90 -21.31 -27.63 – -14.99 1.14 1.13 – 1.56
0.93 -5.59 -17.25 – 6.08 1.10 1.08 – 1.13
0.96 9.15 -5.53 – 23.84 1.07 1.04 – 1.10
1.00 27.43 10.08 – 44.78 1.03 0.99 – 1.07
Comparison between PEF-sp and PEF-pk
The correlation between measurements was
0.943 (95% CI = 0.930 – 0.953).
Error-in-variable regression
When varying the hypothesised reliability be-
tween 0.97 (3% of noise variance on the total vari-
ance) and 1 (no measurement noise), the regres-
sion coefficient varied in the following manner
(tab. 3):
Fig. 2. - a) probability distribution of the differences; b)The quartile plot of the differences; c) Comparison plot: PEFR measurements by Piko vs.
spirometric measurements; d) Bland-Altman plot of the differences together with the 95% limits of agreements.
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Test for normality of the differences
Skewness/Kurtosis tests for normality resulted
χ2 = 48.45, p-value < 0.001; Shapiro-Wilk W test
for normal data resulted z = 6.11, p-value < 0.001.
These tests reject the normality hypothesis.
Figure 2a and 2b indicate that the distance of
the differences from the normal distribution is pro-
nounced, in particular on the right tail of distribu-
tion.
Relationship between difference and magnitude
See fig. 2d and the following regressions. We
first assessed the difference between the two meth-
ods based on the average of the two methods.
Moreover, we assessed the absolute difference
between the two methods on the average of the
two methods (tab. 4; fig. 2d).
In terms of PEFR measurements, a relation-
ship was proved between the differences in the
measurements obtained from the two instruments
and the extent of the measurements themselves.
The bias and the variability of error (such as the
standard deviation) increase by increased the mag-
nitude.
Discussion
Regular (ideally daily) and long-term PEFR
measurements are recommended for assessing
changes in lung function and asthma severity, for
monitoring response to therapeutic treatment, for
evaluating the role of potential triggers, and for
preventing respiratory exacerbations [1-2, 4].
Independently of the need for standardisation
of the many different scales of PEFR charts now
available [14], PEFR measurements are also par-
tially biased by their intrinsic sensitivity and vari-
ability, which are not negligible in real life. If the
former mainly depends on the large “effort depen-
dence” of PEFR measurements in adults, the latter
largely depends on the very low patient compliance
and cooperation in the forced respiratory manoeu-
vres needed to perform PEFR measurements [7-8].
Spirometry also measures FEV1 (as the ab-
solute value in litres) and FEV1 % predicted,
which is the most accepted indicator of the severi-
ty of airway obstruction [15-16]: FEV1 usually
represents the most reliable and reproducible mea-
surement for monitoring respiratory patients even
though it is not as widely available as PEFR for the
patient’s personal check at home or outside the
medical office [17-19]. At present, despite the re-
cent great technological improvements in spirom-
eters’ engineering of recent years, FEV1 measure-
ments are still regarded as possible to perform on-
ly in the presence of a conventional office spirom-
eter, with all the related logistic and procedural
limitations that need to overcome in real life [20].
PIKO-1 is a highly innovative, electronic in-
strument for easily detecting airway obstruction
and for checking and monitoring both PEFR and
FEV1 outside the medical office or clinic. It repre-
sents a substantial improvement in the self-man-
agement of obstructive patients, in particular of
asthmatic patients, who can change their airway
patency suddenly and can frequently need a rapid
self-adjustment of drug assumption for controlling
their respiratory disease.
This handy diagnostic device is based on the
use of a patented flow-sensing mechanism. The
core of this mechanism is a flat spring made out of
a special alloy, developed for space applications,
which offers stainless steel qualities and has very
stable parameters up to 270 °C. The pressure cre-
ated by the air flow produces a deformation of the
flat spring. The deformation is detected by some
extensometers, whose resistance variation is mea-
sured through bridge technology. Since the defor-
mation of the flat spring is proportional to the ap-
plied pressure which is related to the air flow ac-
cording to a known function, it is possible to cal-
culate the air flow itself. This calculation is per-
formed by frequent measurements of the pressure
exerted by the air flow. The measurement is in fact
repeated every 1/100 second.
The electronic section implementing the
bridge technology mechanism also includes fea-
tures for temperature compensation. In fact, the
instrument has a self-compensation feature in the
0-50 °C interval. The accuracy of measurements
is not affected by possible deposition of dirt on the
surface of the spring; the mechanical parameters
of the spring are the only factors in determining
the computed pressure value. The only possible
consequence of dirt deposition on the spring sur-
face is variation of the offset at zero flow condi-
tion. However, this is taken into account by self-
calibration of the instrument when switched on,
and hence the offset is subtracted from the fol-
lowing measurement operations. Only deposition
of dirt disturbing the free movement of the spring
could affect the reading and should be removed.
However, this is unlikely, since it can occur only
in the case of dirt deposition on the inner face of
the spring, which is protected by the instrument
case.
PIKO-1 has also proved to be resistant to age-
ing and environmental stress. As part of the FDA
Table 4. - In respect of the PEFR measurements, a relationship exists between the differences in measures
obtained with the two instruments and the magnitude of measures
Intercept 95% CI Slope 95% CI
Difference -0.30 -17.38 – 16.78 0.09 0.05 – 0.12
Absolute difference 8.97 -4.88 – 22.82 0.09 0.06 – 0.12
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submission by the manufacturer, ten instrument
units underwent 50,000 tests each, with a simulat-
ed air flow of 18 L per second. After this chal-
lenge, each unit was found to have deviated by on-
ly 0.1% from the initial readings.
The other relevant characteristics of PIKO-1,
such as the fact that it is pocket size (35 g weight;
volume 7x5x1.5 cm); has the possibility of setting
predicted values, and the quality control of respi-
ratory manoeuvres, also are of great practical val-
ue for the effective self-management of patients
with airway obstruction. PIKO-1 measurements
proved easy to perform by all patients, indepen-
dently of their original respiratory disease. This
piece of evidence further supports the applicabili-
ty of regular (or daily) self-check of airway paten-
cy’ by all subjects, independently of their clinical
setting. Even though systematically assessed, the
distance between PIKO-1 and spirometrical mea-
surements were not so relevant in such an extent
(such as +4% and -8% respectively) so as to limit
their use in daily life, being the practical advan-
tages highly consistent in terms of patients’ man-
agement, without any possibility to mis-under-
stand the patients’ intrinsic severity.
In conclusion, although the office spirometer is
an irreplaceable instrument for both detecting and
managing patients with airway obstruction even in
primary care, also the use of PIKO-1 should be re-
garded as a very good opportunity, being the im-
plementation of FEV1 as a regular indicator of per-
sonal lung function to assess, register, and monitor
easily, regularly (or daily) and inexpensively at
home or when working the crucial improvement.
Furthermore, when regularly adopted, PIKO-1 can
also facilitate the patients’ awareness of the dis-
ease and encourage their cooperation with the GP,
or the pneumologist, in order to maintain their own
clinical conditions under control.
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